EN DE
Watch CG Oncology, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CG Oncology, Inc. (CGON) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of CG Oncology, Inc. stock $39.43, price $84.78, that is 53.5% below the price, quality 28 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US1569441009

CO CG Oncology, Inc. logo Thin data Nov 17, 2026

CG Oncology, Inc.

CGON · US

Far too expensive (fair value 54% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Expensive Growth (revenue 3y +176.6 %/yr in USD) 
Mixed vs. peers (3/7) 
Recent news mixed 
Insiders bought $24.8M (6M) · sold $2.9M 
Fair value $39.43 · Strongly overvalued 
Quality 28/100 
Negative free cash flow 
Narrow moat 9/100
Thin data 
Estimate

Main risks:

🚩Dependence on single product and Biovire supplier🚩Rivals J&J TAR-200 and ImmunityBio Anktiva
Watch CG Oncology, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$84.78 $15.59 Fair Value $39.43 Jan 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

34‑month range $15.59 – $84.78 · fair‑value band $29.57 – $49.28 · the $84.78 price screens above the $39.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow CG Oncology in your weekly email

Every Wednesday you see whether CG Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

Show moreShow less

The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.

CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Stock analysis

CG Oncology, Inc. (CGON) currently trades at $84.78, while our estimate is $39.43, 54% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $29.57 (bear) to $49.28 (bull), the price of $84.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CG Oncology, Inc. reported revenue of $4.0M in FY2025 versus $10.4M in FY2021, a compound −21.0%/yr. Reported net income was −$161M in FY2025.

Key figures

Market cap $7.5B Mid · EPS (TTM) $−2.72 · Return on equity −28.3% · Return on assets (EBIT) −22.5% (5-year average) · Operating margin −3,943% · Revenue (TTM) $6.2M · Revenue growth (YoY) −3.7% · Free cash flow −$132M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 127% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −54%, CGON screens richer than that median.

Fair Value

Bear $29.57 Fair Value $39.43 Bull $49.28
Price $84.78 · Downside -53.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 82
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $24.8M, on Jun 25, 2026. Over the same period, 2 people sold shares worth $2.9M.

  • SaleLeonard E PostDirector8× since Nov 17, 2025: 16,000 shares, avg. $65.73$1.1MOct 15, 202610b5-1 plan
  • SaleJames MulayDirector5× since Jan 9, 2026: 54,838 shares, avg. $68.98$3.8MJul 10, 202610b5-1 plan
  • BuyBrian Guan-Chyun LiuDirector371,085 shares at $66.87$24.8MJun 25, 202610b5-1 plan

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+254.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+176.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−121.7% (2021) → −4,722.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CGON screens overvalued: fair value 54% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (90 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Note from the team Nov 13, 2026
AI conclusion: Strong cash reserves funding operations through 2029 form the main strength, while large operating losses and negative margins highlight the narrow moat with limited durable advantage.
Main risk: Failure of cretostimogene or issues at supplier Biovire could halt all development and commercialization as it is the company's only product candidate manufactured solely by Biovire.
Bull case: Successful differentiation through durability data and broad indications could allow cretostimogene to become a preferred backbone therapy despite rivals and secure long-term adoption.
Bear case: If the single asset encounters regulatory setbacks or rivals capture patients with scale and combinations, the company could face prolonged losses without viable alternatives.
CG Oncology is pushing cretostimogene as a potential backbone therapy for non-muscle invasive bladder cancer, with topline data from the first randomized Phase 3 trial in intermediate-risk disease due this month and further updates plus a biologics license application targeted for Q4. The company holds nearly a billion dollars in cash equivalents that it projects will cover operations through 2029 despite rising development costs. Will the coming readouts confirm broad applicability across risk groups or expose narrower utility than hoped?
Join the discussion →

Compare CG Oncology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −53.5% · Bottom 25%
Profitability
Return on assets −20.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) −3.7% · Below median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 9.94× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs CGON
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs CGON
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs CGON
argenx SE ARGX $950.95 $908.40 −4% vs CGON
CSL Limited CSL A$199.55 A$186.49 −7% vs CGON
Moderna, Inc MRNA $215.27 $135.64 −37% vs CGON
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs CGON
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs CGON
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs CGON
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs CGON

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CG Oncology, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CG Oncology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CGON

Frequently asked questions

Is CG Oncology, Inc. (CGON) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $39.43 versus a price of $84.78, about 54% lower (overvalued).
What is the fair value of CGON?
Our estimate for CG Oncology, Inc. is $39.43 (as of Nov 17, 2026), built from audited fundamentals. The current price: $84.78.
What is the quality score of CGON?
CG Oncology, Inc. has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CG Oncology, Inc. (CGON)?
Our calculated price target is the estimate of $39.43 (as of Nov 17, 2026). Cautious scenario $29.57, optimistic scenario $49.28. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CG Oncology, Inc. stock forecast for 2026?
Our estimate puts fair value at $39.43, about 54% lower versus a price of $84.78 (overvalued). Cautious scenario $29.57, optimistic scenario $49.28. The calculation is refreshed regularly with new filings.
What is the revenue of CG Oncology, Inc. (CGON)?
CG Oncology, Inc. reported trailing-twelve-month revenue of about $6.2M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of CG Oncology, Inc. (CGON)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CG Oncology, Inc. it is $39.43 per share (as of Nov 17, 2026), against a price of $84.78.
Is CG Oncology, Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, CGON trades above its calculated fair value: price $84.78, fair value $39.43, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CGON?
No. The price is what the market pays today ($84.78); the fair value is what the company's own numbers justify ($39.43). For CG Oncology, Inc. the two are $45.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is CG Oncology, Inc. worth?
The market values CG Oncology, Inc. at about $7.5B (market capitalisation, as of Nov 17, 2026). Per share that is $84.78; our models calculate a fair value of $39.43 per share.
What do the bullish and bearish scenarios say about CGON?
Our models span a range for CG Oncology, Inc.: cautious scenario $29.57, base $39.43, optimistic $49.28 per share (as of Nov 17, 2026, price $84.78). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CG Oncology, Inc. (CGON)?
Balance-sheet figures for CG Oncology, Inc. (as of Nov 17, 2026): return on equity −28.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is CGON from its 52-week high?
CG Oncology, Inc. trades at $84.78, at its 52-week high of $84.78 and 127% above the low of $37.37 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $39.43 is for.
Which stocks are comparable to CG Oncology, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CG Oncology, Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price $84.78, calculated fair value $39.43 (−54%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. CG Oncology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CG Oncology, Inc. (CGON)?
The closing price on Nov 16, 2026 was $84.78. Our estimate is $39.43, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CG Oncology, Inc. right now?
The price sits above even our optimistic bull case ($49.28). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CG Oncology, Inc.

How large is the market capitalisation of CG Oncology, Inc. (CGON)?
The market capitalisation of CG Oncology, Inc. is $7.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CG Oncology, Inc. (CGON)?
Earnings per share at CG Oncology, Inc. are $−2.72. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CG Oncology, Inc. (CGON)?
The return on equity (ROE) of CG Oncology, Inc. is −28.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CG Oncology, Inc. (CGON)?
On an EBIT basis the return on assets of CG Oncology, Inc. is −22.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CG Oncology, Inc. (CGON)?
The operating margin of CG Oncology, Inc. is −3,943% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CG Oncology, Inc. (CGON)?
Revenue at CG Oncology, Inc. is down 3.7% versus a year earlier (3y avg +177%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CG Oncology, Inc. (CGON) generate?
The free cash flow of CG Oncology, Inc. is −$132M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CG Oncology, Inc. (CGON) hold?
CG Oncology, Inc. holds more cash than debt, $25.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CG Oncology, Inc. in the live analysis

One click puts CG Oncology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.